Thermo Fisher Scientific’s new Invitrogen TrueCut Hifi Cas9 protein is designed for research applications that require highly precise genome editing, such as chimeric antigen receptor (CAR) TT cell engineering and cell model building for the discovery of diseases. Launched at the end of November 2021, the new protein considerably minimizes off-target events while maintaining maximum editing efficiency on the target.

Invitrogen TrueCut HiFi Cas9 protein complements Thermo Fisher’s existing portfolio of clustered evenly spaced short palindromic repeat (CRISPR) genome editing solutions by minimizing changes in unforeseen locations, the company said in a release from press of November 30, 2021 are very disruptive in the translation of research, drug screening and drug modeling. According to Thermo Fisher, the protein demonstrates almost complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs). The company also said that it has demonstrated improved off-target profiles compared to other products on the market in the release.

“Our pharmaceutical and biotech customers are looking for very precise and precise solutions to harness the power of CRISPR genome editing,” said Brandon Pence, vice president and general manager of cell biology at Thermo Fisher Scientific, in the press release. hurry. “Nothing is more disappointing than discovering months after a change that the biological response you are measuring was due to an unintentional off-target change. The new Invitrogen TrueCut HiFi Cas9 protein gives researchers the confidence that their changes took place there. where they expected, not elsewhere in the genome. “